| Moderated By: caly -- (Moderated) -- Started: 12/17/2004 1:24:22 AM Revision History |Website: clinuvel.com
Australian Exchange: finance.yahoo.com
pinksheets.com quote: pinksheets.com
Australian Message Board: sharescene.com
Clinuvel Pharmaceuticals Limited (formerly Epitan Limited) is a Melbourne based pharmaceutical company focused on dermatology.
The leading drug candidate currently in Phase II clinical trials is CUV1647 (formerly EPT1647/MelanotanTM). CUV1647 is being developed as a prophylactic photoprotective agent for two indications:
1. Polymorphous Light Eruption (PLE)
2. Actinic Keratosis (AK)
Clinuvel may expand the number of clinical indications for CUV1647.
CUV1647 acts by increasing the levels of eumelanin in the skin; it appears to shield against subsequent prolonged UV irradiation (UVR). CUV1647 is delivered from a subcutaneous implant approximately the size of a grain of rice. Increased pigmentation of the skin appears after a few days and may last up to several months. It is proposed that CUV1647 will treat the millions of people world-wide who suffer from UV-related skin disorders such as PLE and AK.